66291-30-3

Basic information

• Product Name: cyclopropanecarbaldehyde oxime
• CAS NO: 66291-30-3
• Molecular Formula: C₄H₇NO
• Molecular Weight: 85.1045
• Mol File: 66291-30-3.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 161.7°C at 760 mmHg
• Flash Point: 74.3°C
• Density: 1.22g/cm³
• Vapor Pressure: 1.16mmHg at 25°C
• Refractive Index: 1.553
• CAS DataBase Reference: cyclopropanecarbaldehyde oxime(CAS DataBase Reference)
• NIST Chemistry Reference: cyclopropanecarbaldehyde oxime(66291-30-3)
• EPA Substance Registry System: cyclopropanecarbaldehyde oxime(66291-30-3)

Safety Data

• Hazardous Substances Data: 66291-30-3(Hazardous Substances Data)

Upstream product

• 1489-69-6 Cyclopropanecarboxaldehyde 

Downstream Products

• 1315307-39-1 1-(4-fluorophenyl)-3-methoxycarbonyl-5-cyclopropyl-1,2,4-triazole 

Relevant articles and documents

BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE

Benzimidazole compounds of formula (I), shown below, are disclosed. The compounds are potent human glutaminyl cyclase inhibitors. Also disclosed is a pharmaceutical composition containing one of these compounds and a pharmaceutical acceptable carrier, as well as a method of treating Alzheimer's disease or Huntington's disease by administering to a subject in need thereof an effective amount of such a compound.

HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', R2 R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES

2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.